About
BioGeneration Ventures (BGV) is the early-stage strategy of the Forbion-BGV platform of funds, which also includes Forbion Ventures and Forbion Growth. BGV has been located with Forbion in Naarden (NL) since its inception.
BGV invests in partnerships with other professional investors in life sciences and has built strategic relationships with various academic institutions and leading healthcare companies as well as venture capital investors in the Netherlands, the EU, and the US.
BGV has strategic partnerships with pharma companies as well as clinical and pre-clinical research and pharmaceutical manufacturing service companies. BGV and its portfolio companies benefit from direct access to board know-how and capabilities of these partners as well as preferential terms for services.
BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds, and private investors. Strategic investors include Eli Lilly and Company, Novo Holdings, and Bristol Myers Squibb.
Investment criteria
Pre-seed
—
Seed
Invests
Series A
Invests
Series B
Invests
Growth
—
- Sectors
- Healthcare & Life SciencesVenture Capital & Private Equity
- Geographies
- Belgium · Canada · Germany · Netherlands · United Kingdom · United States
- Round role
- Leads and co-leads rounds
Highlights
Highlights coming soon
Notable work and milestones will show up here.

